Dr Fadi-jean Saad, MD | |
18263 E 10 Mile Rd, Suite D, Roseville, MI 48066-5805 | |
(586) 778-3478 | |
(586) 778-3496 |
Full Name | Dr Fadi-jean Saad |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 28 Years |
Location | 18263 E 10 Mile Rd, Roseville, Michigan |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174573810 | NPI | - | NPPES |
487600010 | Medicaid | MI |
Facility Name | Location | Facility Type |
---|---|---|
Beaumont Hospital, Troy | Troy, MI | Hospital |
Ascension Macomb Oakland Hosp-warren Campus | Warren, MI | Hospital |
Entity Name | Emad Alatassi Md, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447457734 PECOS PAC ID: 6204860463 Enrollment ID: O20050927000225 |
News Archive
Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.
IMEC, a leading European research center in nanotechnology, the Institüt für Mikrotechnik Mainz (IMM), one of the leading European research centers in microfluidics, and their partners within the European Sixth Framework Project MASCOT achieve a major milestone in the development of a lab-on-chip for the detection and therapy evaluation of breast cancer.
Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.
How do forensic scientists deal with complex DNA-evidence found at crime scenes? Giulia Cereda developed new statistical models to analyse them.
Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $31 million Series B financing. New investor Novo A/S is leading the round, joined by original investors, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.
› Verified 2 days ago
Entity Name | Fadi-jean Saad Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801552708 PECOS PAC ID: 1759772668 Enrollment ID: O20220104002120 |
News Archive
Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.
IMEC, a leading European research center in nanotechnology, the Institüt für Mikrotechnik Mainz (IMM), one of the leading European research centers in microfluidics, and their partners within the European Sixth Framework Project MASCOT achieve a major milestone in the development of a lab-on-chip for the detection and therapy evaluation of breast cancer.
Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.
How do forensic scientists deal with complex DNA-evidence found at crime scenes? Giulia Cereda developed new statistical models to analyse them.
Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $31 million Series B financing. New investor Novo A/S is leading the round, joined by original investors, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Fadi-jean Saad, MD 18263 E 10 Mile Rd, Suite D, Roseville, MI 48066-5805 Ph: (586) 778-3478 | Dr Fadi-jean Saad, MD 18263 E 10 Mile Rd, Suite D, Roseville, MI 48066-5805 Ph: (586) 778-3478 |
News Archive
Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.
IMEC, a leading European research center in nanotechnology, the Institüt für Mikrotechnik Mainz (IMM), one of the leading European research centers in microfluidics, and their partners within the European Sixth Framework Project MASCOT achieve a major milestone in the development of a lab-on-chip for the detection and therapy evaluation of breast cancer.
Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.
How do forensic scientists deal with complex DNA-evidence found at crime scenes? Giulia Cereda developed new statistical models to analyse them.
Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $31 million Series B financing. New investor Novo A/S is leading the round, joined by original investors, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.
› Verified 2 days ago
Robert Lewis Marchese, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 25810 Kelly Rd, Suite 3, Roseville, MI 48066 Phone: 586-777-9724 Fax: 586-777-9725 | |
Benjamin O Osowa, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18263 E 10 Mile Rd, Suite E, Roseville, MI 48066 Phone: 586-552-8696 Fax: 586-552-4404 | |
Dr. Majid Alzagoum, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18303 E 10 Mile Rd, Suite 100, Roseville, MI 48066 Phone: 586-776-8877 Fax: 586-776-3092 | |
Dr. Wahed Ishaqsei, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 18263 E 10 Mile Rd, Suite D, Roseville, MI 48066 Phone: 586-778-4950 Fax: 586-778-4952 | |
Dr. Mohamad K. Ajjour, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18303 E 10 Mile Rd, Suite 100, Roseville, MI 48066 Phone: 586-776-8877 Fax: 586-776-3092 | |
Dr. Ameer Abdulrazzak, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18001 E 10 Mile, Suite 1, Roseville, MI 48066 Phone: 586-218-5800 Fax: 586-218-5808 | |
Dr. Madjid Mesgarzadeh, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 25910 Kelly Rd, Suite B, Roseville, MI 48066 Phone: 586-772-3366 Fax: 586-772-3355 |